| |
1 stAB Concentration 0.0005 serum/PBS
|
1 stAB Concentration 0.001 serum/PBS
|
1 stAB Concentration 0.005 serum/PBS
|
1 stAB Concentration 0.01 serum/PBS
|
|
Kd (μg/ml)
|
0.49 ± 0.25
|
0.89 ± 0.56
|
0.49 ± 0.097
|
0.24 ± 0.06
|
|
Amax (OD units)
|
0.076 ± 0.01
|
0.12 ± 0.01
|
0.22 ± 0.012
|
0.35 ± 0.024
|
|
D (OD units)
|
0.29 ± 0.008
|
0.3 ± 0.015
|
0.29 ± 0.009
|
0.3 ± 0.02
|
|
B: increasing added antibody at three fixed levels of attached peptide
|
| |
Attached peptide 0.25 μg/ml
|
Attached peptide 0.5 μg/ml
|
Attached peptide 1 μg/ml
| |
|
Kd (serum dilutions)
|
0.003 ± 0.0007
|
0.003 ± 0.001
|
0.001 ± 0.0002
| |
|
Amax (OD units)
|
0.35 ± 0.023
|
0.56 ± 0.06
|
0.49 ± 0.02
| |
|
D (OD units)
|
0.38 ± 0.01
|
0.38 ± 0.02
|
0.38 ± 0.01
| |
|
C: Competition assay – Kd determined when increasing added free peptide at two fixed levels of attached peptide
|
| |
Attached peptide 0.25 μg/ml
|
Attached peptide 0.5 μg/ml
| | |
|
Kd (μg/ml)
|
0.14 ± 0.03
|
0.97 ± 0.15
| | |
|
Amax (OD units)
|
0.29 ± 0.019
|
0.37 ± 0.016
| | |
|
D (OD units)
|
0.39 ± 0.01
|
0.35 ± 0.01
| | |
